Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Influence Of Familial Pancreatic Cancer On Postoperative Outcome In Pancreatic Cancer: Relevance To Adjuvant Chemotherapy

K. Tezuka, Y. Okamura, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, R. Ashida, K. Ohgi, K. Uesaka
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Familial pancreatic cancer (FPC) is defined as a family in which at least two first-degree relatives have pancreatic cancer (PC). The prognostic significance of PC in an FPC family after surgery is not fully understood. This was a retrospective study of 427 patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma between January 2008 and December 2016. PC patients who also had at least one first-degree relative with PC were defined as FPC patients. The associations between recurrence and clinicopathological characteristics were analyzed for both FPC and non-FPC patients. FPC patients accounted for 31 of the 427 (7.3%) patients. Recurrence occurred in 72.1% of the total cohort and in 87.1% of the 31 FPC patients. Multivariate analysis showed that being an FPC patient was an independent predictor for relapse-free survival (RFS) (hazard ratio [HR] 1.52, P = 0.038). Although univariate analysis revealed that being an FPC patient was significantly associated with poorer overall survival (OS) (P < 0.001), multivariate analysis showed that being an FPC patient was not an independent predictor for OS (P = 0.164). Dichotomization of the 427 patients into those who received (n = 317: 17 FPC and 300 non-FPC patients) and did not receive (n = 110: 14 FPC and 96 non-FPC patients) adjuvant chemotherapy revealed that being an FPC patient was an independent predictor for RFS (HR 2.50, P < 0.001) and OS (HR 2.30, P = 0.003) only for patients who received adjuvant chemotherapy. This study has shown that being an FPC patient is a significant prognostic indicator for PC patients who undergo resection and receive adjuvant chemotherapy.
This paper references
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
H. Oettle (2013)
Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012
K. Wada (2013)
SEER Cancer Statistics Review, 1975-2003
L. Ries (2006)
Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis
M. Mavros (2015)
Patterns of Pancreatic Resection Differ Between Patients with Familial and Sporadic Pancreatic Cancer
J. Barton (2011)
Assessment of “Gene–Environment” Interaction in Cases of Familial and Sporadic Pancreatic Cancer
T. Yeo (2009)
Survival in Familial Pancreatic Cancer
J. Ji (2008)
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium
M. Goggins (2019)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy (2018)
Advanced-stage pancreatic cancer: therapy options
J. Werner (2013)
Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer.
T. Sugiura (2013)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla (2019)
Clinical and pathologic features of familial pancreatic cancer
Jeremy L. Humphris (2014)
Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
A. Ohmoto (2019)
Germline mutations in Japanese familial pancreatic cancer patients
Erina Takai (2016)
Familial and sporadic pancreatic cancer share the same molecular pathogenesis
Alexis L. Norris (2014)
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
S. Syngal (2015)
Microscopic Venous Invasion in Pancreatic Cancer
M. Yamada (2017)
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
A. Blair (2018)
Neoadjuvant Treatment for Pancreatic Cancer.
Alexander G Raufi (2019)
A histomorphologic comparison of familial and sporadic pancreatic cancers.
A. Singhi (2015)
Age of onset in familial cancer.
A. Brandt (2008)
Anticipation in familial pancreatic cancer
C. McFaul (2006)
Risk factors associated with earlier age of onset in familial pancreatic carcinoma
T. James (2004)
International Union Against Cancer. TNM classification of Malignant Tumours
JD Brierley (2017)
Prevalence of familial pancreatic cancer in Germany
D. Bartsch (2004)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay (2019)
Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kickoff meeting at International Symposium on Pancreas
K Wada (2012)
Familial pancreatic cancer.
M. Grajower (1983)
Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds
A. Klein (2004)
Progress report: familial pancreatic cancer
I. Mintziras (2019)
SEER data submission, posted to the SEER web site
M D Bethesda
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M Wattenberg (2019)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
K. Uesaka (2016)
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
T. Kondo (2018)
Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
F. Motoi (2020)
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
N. Roberts (2016)

Semantic Scholar Logo Some data provided by SemanticScholar